



ASX Announcement

3 September 2021

Review of FY21 - Investor Webinar

MELBOURNE, AUSTRALIA (3 September 2021): Hexima Limited (ASX:HXL) a clinical-stage biotechnology company developing pezadeftide (formerly HXP124), as a potential new prescription topical treatment for onychomycosis, today announces that, following the filing of its Annual Report for the year to 30 June 2021 with ASX, management will hold a shareholder webinar on 8 September 2021 at 10:00 AM.

The purpose of the webinar is to review the achievements of FY21 and to inform investors of expected important developments and milestones. Hexima's management appreciates the role that shareholders have played in the progress of the Company, and looks forward to updating attendees on the Company's clinical and commercial progress.

The Company will also allow additional time for questions and answers, and welcome the submission of questions in advance. Please send questions or comments to info@hexima.com.au, and management will attempt to address them during the webinar.

To register for the webinar, click on the link below:

Investor Webinar: 8 September 2021, 10 AM AEST

Registration link: https://us06web.zoom.us/webinar/register/WN_FU4G4--9QGGU55LOfZkTSA

A copy of the presentation will be filed with ASX on the morning of 8 September and the webinar in its entirety will be accessible after its conclusion via the Investors section of Hexima's website:

<https://investors.hexima.com.au/investor-centre/?page=presentations-and-media>

This announcement is authorised for release to ASX by Michael Aldridge, CEO

Enquiries:

Dr Nicole van der Weerden

Chief Operating Officer

n.vanderweerden@hexima.com.au

Join our email database to receive company announcements:

info@hexima.com.au

www.hexima.com.au

About Hexima

Hexima (ASX:HXL) is a clinical stage, anti-infectives focused biotechnology company engaged in the research and development of defensin peptides for applications as human therapeutics. Our lead product candidate, pezadeftide (HXP124) applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting an Australian phase IIb clinical trial testing pezadeftide for the treatment of onychomycosis. Hexima holds granted, long-life patents protecting pezadeftide in major markets globally. For additional information please visit www.hexima.com.au. You can also find us on [Twitter](#) and [LinkedIn](#).